Outcome of patients with multiple myeloma (MM) relapsing after front-line autologous stem cell transplantation (ASCT): Impact of reduced intensity allogeneic transplantation (RICALLO).

e19564 Background: The aim of this single centre study was to assess the outcome of pts with MM following the relapse after ASCT, according to whether or not a RICALLO was performed. Methods: Records of the patients were reviewed and the criteria for entering the study were: Symptomatic MM treated frontline with a program including single or double ASCT, relapse at any time following ASCT, up to 65 y.o at relapse, response (CR, VGPR or PR) to a second line treatment. RICALLO was proposed to pts with no significant co-morbidities, having either sibling or MUD and who gave their consent after precise information on the risk of the RICALLO. Results: 125 pts, between 04/2002 and 10/2012 fulfilling the inclusion criteria were identified. 32 pts received a RICALLO within a median of 7 months (2-35) after relapse. The RIC consisted of fludarabine plus either 2Gy ICT or busulfan and ATG. The graft was PBSC from sibling in 12 pts and from MUD in 20 pts. Ninety three pts (CT group) received therapies according to o...